Jean-François Beaulieu, Ph. D.

Jean-François BeaulieuInvestigator
Mother & Child Axis
Centre de recherche du CHUS

Canada Research Chair in Intestinal Physiopathology

Full Professor
Department of Anatomy and Cell Biology
Faculty of Medicine and Health Sciences
Université de Sherbrooke

Contact Information
Phone | 819 564-5269
E-Mail |


Research relevance

Study of the renewal mechanisms of cells that form the inner wall of the human digestive system

Gastrointestinal disease is the second leading cause of hospitalization and the fourth leading cause of temporary disability in Canada. The direct cost of gastrointestinal disease to the Canadian health care system and for business has been estimated at $100 billion annually.

Director of a research team supported by the Canadian Institutes of Health Research and the Canada Research Chair program (approximately $832,000/per year for 5 years), the investigator Jean-François Beaulieu’s research concerns the mechanisms that regulate intestinal epithelial cell renewal. These highly complex and poorly understood mechanisms contribute to numerous intestinal diseases such as colorectal cancer, intestinal inflammatory disease and ulcers. Doctor Beaulieu’s research has significantly advanced the scientific knowledge of how intestinal cells function.

One of the main research objectives pursued by Doctor Beaulieu’s team is to explain the mechanisms that regulate gene expression in cells that form the human intestinal system, both healthy and diseased. Doctor Beaulieu’s work concerns the regulatory influences generated by the interactions between epithelial cells and the proteins of the extracellular matrix. His team’s research results are expected to lead to the development of new treatments for numerous forms of gastro-intestinal ailments.


To top

Representative Achievements

  • Team leader of the CIHR Team on digestive epithelium ($4.3 M grant, 2007-2012) for research into digestive tube diseases
  • Fellow of the American Gastrointestinal Association (AGA), the highest distinction awarded by the AGA
  • Research grants totalling over $10 M (over the past 10 years) from granting agencies with peer review boards (FRSQ, VRQ, FCAR, CIHR)


Know-How & Opportunities for Collaboration

  • Expert in the characterization and use of experimental human cell models for the analysis of the regulation of gene expression (microarrays, qPCR, shRNA)
  • Specialist of receptors (integrins and non-integrins) for extracellular matrix proteins and their implication in cancer and intestinal inflammatory diseases
  • Multiple international technological exchanges (human intestinal cell lines, human transcription factors, promoters, etc.)
  • Identification and validation of specific markers for early detection of colorectal cancer and the diagnostics of intestinal diseases in the newborn child


To top